Suzanne George, MD, on Soft-Tissue Sarcoma: Evolving Treatment

2017 NCCN Annual Conference

Suzanne George, MD, of Dana-Farber Cancer Institute, discusses current and emerging systemic therapies for soft-tissue sarcoma and the options for multimodality treatment.

Elizabeth R. Plimack, MD, on Bladder Cancer: Management Updates

Elizabeth R. Plimack, MD, of Fox Chase Canc...

Gynecologic Cancers

ASCO Post

Christina S. Chu, MD, on HPV and Cervical/Vulvar Cancer

Christina S. Chu, MD, of Fox Chase Cancer C...

Hematologic Malignancies

Ruben A. Mesa, MD, on Myeloproliferative Neoplasms and Myelofibrosis: New Treatment Guidelines

Ruben A. Mesa, MD, of the Mayo Clinic Cance...

Lymphoma

Leo I. Gordon, MD, on Hodgkin Lymphoma: Management Strategies

Leo I. Gordon, MD, of the Robert H. Lurie C...

Pancreatic Cancer

Margaret A. Tempero, MD, on Pancreatic Cancer: Active Systemic Treatment

Margaret A. Tempero, MD, of the UCSF Helen ...

Sep

Today In Oncology

Suzanne George, MD, on Soft-Tissue Sarcoma: Evolving Treatment

Related Videos

Elizabeth R. Plimack, MD, on Bladder Cancer: Management Updates

Christina S. Chu, MD, on HPV and Cervical/Vulvar Cancer

Ruben A. Mesa, MD, on Myeloproliferative Neoplasms and Myelofibrosis: New Treatment Guidelines

Leo I. Gordon, MD, on Hodgkin Lymphoma: Management Strategies

Margaret A. Tempero, MD, on Pancreatic Cancer: Active Systemic Treatment

Caring for Undocumented Patients With Cancer

First-Line PD-1 Inhibitor With or Without Chemotherapy vs Chemotherapy Alone in Advanced Gastric Cancer

Osimertinib vs Platinum/Pemetrexed in Patients With EGFR T790M Advanced NSCLC

Addition of Veliparib to Carboplatin/Paclitaxel in Previously Treated Patients With BRCA-Mutated Advanced Breast Cancer

Does Binimetinib Improve Progression-Free Survival in Recurrent or Persistent Low-Grade Serous Ovarian Carcinomas